bismuth + tetracycline + metronidazole + omeprazole

Bismuth + tetracycline + metronidazole + omeprazole is a bismuth-based quadruple therapy (BQT) regimen used for the eradication of *Helicobacter pylori* infection. This combination therapy is particularly effective in regions with high resistance to clarithromycin. The regimen includes bismuth (which exerts direct antimicrobial effects and prevents bacterial adhesion), two antibiotics (tetracycline, which inhibits protein synthesis, and metronidazole, which disrupts DNA), and omeprazole (a proton pump inhibitor that reduces gastric acidity to enhance antibiotic stability and efficacy). This specific study by Beni-Suef University evaluates the prevalence of asymptomatic *H. pylori* in patients undergoing percutaneous coronary intervention (PCI) and the impact of this eradication therapy on reducing gastrointestinal symptoms and bleeding risks associated with dual antiplatelet therapy.

Other names

Bismuth-based quadruple therapyBQT